Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Cyproheptadine and Chlorpromazine Effects on Spasticity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Alberta
ClinicalTrials.gov Identifier:
NCT01509885
First received: January 10, 2012
Last updated: November 16, 2012
Last verified: November 2012

January 10, 2012
November 16, 2012
July 2010
November 2012   (final data collection date for primary outcome measure)
  • Cutaneomuscular Reflex Responses [ Time Frame: Change after drug intake at baseline, 30minutes, 60minutes, 90minutes and 120minutes ] [ Designated as safety issue: No ]
    Tibialis anterior reflex responses evoked by stimulation of the medial arch of the foot will be measured before and after drug administration.
  • Paired motor unit recordings [ Time Frame: Change at baseline and 30, 60, 90 and 120min after drug intake ] [ Designated as safety issue: No ]
    We obtain paired motor unit recordings to determine changes in neuronal excitability after drug intake in incomplete spinal-cord injured subjects only.
Same as current
Complete list of historical versions of study NCT01509885 on ClinicalTrials.gov Archive Site
Blood pressure and Heart rate [ Time Frame: Change at baseline and 30, 60, 90, 120 minutes after drug intake ] [ Designated as safety issue: Yes ]
We measure blood pressure and heart rate to determine the safety of the drug during the experiment and whether we can continue safely.
Same as current
Not Provided
Not Provided
 
Cyproheptadine and Chlorpromazine Effects on Spasticity
Phase 3 Study of Cyproheptadine and Chlorpromazine Effects on Spasticity After Spinal Cord Injury

The main goal of this research is to understand the neuronal mechanisms that mediate the development of spasticity and motor dysfunction after spinal cord injury. The investigators examine how neurons and neuronal circuits in an injured nervous system adapt to produce the uncontrolled and unwanted muscle contractions that affect the majority (80%) of patients with spinal cord injury. One of the neurons that the investigators study is the motoneuron that excites the muscles of the limbs to produce movement. Previously, the investigators have shown that after spinal cord injury, the excessive and uncontrolled activity of motoneurons during muscle spasms is mediated, in large part, by the activation of calcium currents in the human motoneuron. In human patients the investigators have used recordings from single muscle fibres to estimate the contribution of these calcium currents in activating the motoneuron during muscle spasms. In this proposal, the investigators study why motoneurons recover these calcium currents and self-sustained activity after chronic spinal cord injury. Because the calcium currents require the presence of the monoamine serotonin (5HT) to activate, and this monoamine is greatly reduced after injury, the investigators examine if the calcium currents recover because the 5HT receptors become spontaneously active without the need for 5HT to bind to the receptor, which the investigators hypothesize to be one of the causes of spasticity after spinal cord injury. This research will pave the way to develop new pharmacological and rehabilitative therapies to both control spasticity after spinal cord injury and augment residual motor movements.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample

Spinal Cord Injury Patients

  • Spinal Cord Injuries
  • Muscle Spasticity
Not Provided
  • Complete Spinal Cord Injured Subjects
    Patients with no motor scores in their legs and suffering a complete spinal cord injury.
  • Incomplete Spinal Cord Injured Subjects
    Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RL, Ballou EW, Anelli R, Heckman CJ, Mashimo T, Vavrek R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K. Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors. Nat Med. 2010 Jun;16(6):694-700. doi: 10.1038/nm.2160. Epub 2010 May 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must have suffered a trauma to the spinal cord at least 6 months ago or longer. In addition, subjects must exhibit some degree of spasticity as determined by having an Ashworth Spasticity Score, as assessed by a physical therapist, greater than 1.

Exclusion Criteria:

  • If patients have damage to the nervous system other than to the spinal cord
  • Pregnant women
  • Elderly Patients and debilitated patients
  • Alcoholic Patients
  • Patients with:

    • Known or suspected allergy to the medication or its ingredients
    • Cardiovascular disease
    • Hypotension
    • Coronary artery disease
    • Reduced liver or kidney function
    • Comatose or depressed states due to CNS depressants
    • Blood dyscrasias
    • Bone marrow depression
    • History of seizures
    • Respiratory problems
    • Hypocalcemia
    • Monoamine oxidase inhibitor therapy
    • Angle-closure glaucoma
    • Stenosing peptic ulcer
    • Symptomatic prostatic hypertrophy
    • Bladder neck obstruction
    • Pyloroduodenal obstruction
    • History of bronchial asthma
    • Increased intraocular pressure
    • Hyperthyroidism
    • Cardiovascular disease
    • Hypertension
  • Patients taking:

    • Amphetamines
    • Antihistamines-second generation
    • Anticonvulsants
    • Anticholinergics
    • CNS depressants
    • Antidepressants
    • Hypotensive agents
    • Levodopa
    • Lithium
Both
17 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT01509885
Pro00020682
Not Provided
University of Alberta
University of Alberta
Not Provided
Principal Investigator: Monica A Gorassini, PhD University of Alberta
University of Alberta
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP